The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

Martinez-Velez, N. (Naiara); Garcia-Moure, M. (Marc); Marigil, M. (Miguel); Gonzalez-Huarriz, M. (Marisol); Puigdelloses-Vallcorba, M. (Montserrat); Gallego-Perez-Larraya, J. (Jaime); Zalacain, M. (Marta); Marrodán, L. (Lucía); Varela-Guruceaga, M. (Maider); Laspidea, V. (Virginia); Aristu-Mendioroz, J.J. (José Javier); Ramos, L.I. (Luis Isaac); Tejada-Solis, S. (Sonia); Diez-Valle, R. (Ricardo); Jones, C. (Chris); Mackay, A. (Alan); Martinez-Climent, J.A. (José Ángel); García-Barchino, M.J. (María José); Raabe, E. (Eric); Monje, M. (Michelle); Becher, O.J. (Oren J.); Junier, M.P. (Marie Pierre); El-Habr, E. (Elías); Chneiweiss, H. (Hervé); Aldave, G. (Guillermo); Jiang, H. (Hong); Fueyo, J. (Juan); Patiño-García, A. (Ana); Gomez-Manzano, C. (Candelaria); Alonso-Roldán, M.M. (Marta María)

Keywords:

Materias Investigacion::Ciencias de la Salud::Oncología

Issue Date:

2019

Publisher:

Springer Science and Business Media LLC

Project:

817884 - ViroPedTher - Oncolytic viruses for the treatment of pediatric brain tumors: An integrated clinical and lab approach

ISSN:

2041-1723

Note:

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Citation:

Martinez-Velez, N. (Naiara); Garcia-Moure, M. (Marc); Marigil, M. (Miguel); et al. "The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models". Nature Communications. 10 (2235), 2019, 1 - 10

Abstract

Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs. Our results show that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited against the tumor. Altogether, our data highlight the potential of this virus as treatment for patients with these tumors. Of clinical significance, these data have led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG (NCT03178032).

URI:

https://hdl.handle.net/10171/62393

DOI:

10.1038/s41467-019-10043-0

Appears in Collections:

DA - CUN - Neurocirugía - Artículos de revista
DA - CUN - Neurología - Artículos de revista
DA - CUN - Oncología radioterápica - Artículos de revista
DA - CUN - Pediatría - Artículos de revista

Files in This Item: